Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748638 | 1.00 | NPC1 (0.38) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6748679 | 1.00 | NPC1 (0.38) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6745081 | 1.00 | NPC1 (0.38) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6748631 | 0.95 | ALDH1A1 (0.38) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6748582 | 0.95 | ALDH1A1 (0.38) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6748677 | 0.95 | ALDH1A1 (0.38) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6749469 | 0.95 | ALDH1A1 (0.38) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6748529 | 0.95 | ALDH1A1 (0.38) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6748685 | 0.94 | ALDH1A1 (0.39) | NPC1RAB9AAPPTDP1CYP2C19 | |
| SCHEMBL6748706 | 0.94 | NPC1 (0.35) | NPC1RAB9ANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696588-B2 | OXIDATION POTENTIAL OF .3-1.5 V ON THE BASIS OF A STANDARD HYDROGEN ELECTRODE, ALKOXY AND AROMATIC AMINE DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-02-24 | — | — | US | disclosed |
| EP-0861845-B1 | Silicon-containing compound and organic electroluminescence device using the same | SUMITOMO CHEMICAL CO (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-20020115877-A1 | Silicon-containing compound and organic electroluminescence device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-08-22 | — | — | US | disclosed |
| US-6369258-B1 | SILICON COMPOUND WITH OXIDATION POTENTIAL ON HYDROGEN ELECTRODE POTENTIAL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-04-09 | — | — | US | disclosed |
| EP-0861845-A2 | Silicon-containing compound and organic electroluminescence device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115877-A1 | Silicon-containing compound and organic electroluminescence device using the same | EPCAM, PIEZO1, OR10J3 | NPC1 4618/4885RAB9A 2705/4885NFKB1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.